Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Dan Spillane who wrote (1832)	3/26/1999 10:01:00 PM
From: Anthony Wong	Respond to of 2539

There is some coverage, but definitely not headline news. itn.co.uk:80/World/world19990324/032406w.htm

To: Dan Spillane who wrote (1832)	3/26/1999 10:25:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

'Terminator gene' must be resisted by NZ - Delamere The Press, New Zealand March 25, 1999 WELLINGTON -- Associate Health Minister Tuariki Delamere says genetic engineering of modified crops to stop farmers saving seeds from their own plants must be resisted by New Zealand. He criticised the "terminator gene" being developed in the United States by the biotechnology company Monsanto while speaking to a public forum in Wellington on genetically modified organisms. The US Department of Agriculture and a private seed company, Pineland and Delta, have patented a way to make plants produce sterile seeds. Environmentalists have protested that multi-national companies could therefore control food supplies by denying farmers the practice of saving seeds from each harvest for planting. Monsanto has since bought Pineland and Delta and lobbied to get exclusive rights to the sterile seed patent, although so far no seed has been produced containing a terminator gene. Mr Delamere said this technology must be resisted. "The only purpose that I can see for it is to extort usurious profits at the expense of farmers and consumers." Critics of the technology say that farmers might be forced to buy so-called "terminator" seeds when a bad crop left them short of seeds. Scientists worry that pollen from "terminator" plants could alter other crops in an area and make them sterile. -- NZPA press.co.nz

To: Dan Spillane who wrote (1832)	3/27/1999 12:56:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

IMS Health Reports Celebrex U.S. Prescriptions Dispensed Reach 299,571 in Third Week of March (Last updated 4:27 PM ET March 26) LONDON (BW HealthWire) - IMS HEALTH (NYSE:RX) today reported that for the week ending March 19, total Celebrex prescriptions dispensed in the U.S. reached 299,571, up 7.3 percent from the previous week. The rate of mail order prescriptions rose as well, up 5.4 percent from the second week of March, to 16,128 prescriptions. IMS HEALTH's regular weekly prescription activity report covering the week ending March 19 becomes available on Monday, March 29. IMS HEALTH is the world's leading provider of information solutions to the pharmaceutical and healthcare industries. In the ten weeks since its introduction in the U.S., a total of 1.5 million Celebrex prescriptions have been dispensed. The majority of weekly Celebrex prescriptions continues to be new prescriptions, which represented 82 percent of prescribing for the week ending March 19. The remaining 18 percent, or 53,620 Celebrex prescriptions, were refills. IMS HEALTH's weekly prescription tracking service provides comprehensive coverage of three U.S. retail channels -- chain drugstores, independent pharmacies and food stores with pharmacies -- and includes cash and Medicaid prescriptions as well as third-party reimbursement. The service also provides unique access to mail-order prescriptions, making it the most complete market tracking service covering the U.S. pharmaceutical industry. IMS HEALTH is the world's leading provider of information solutions to the pharmaceutical and healthcare industries. With more than $1.2 billion in 1998 revenue, IMS HEALTH operates in over 90 countries. IMS HEALTH is the largest pharmaceutical manufacturer information partner, with over 40 years' experience in the industry. Key products and services integral to customer day-to-day operations include: market research for prescription and over-the-counter pharmaceutical products; sales management information to optimize sales force productivity; technology-enabled selling solutions for sales and marketing decision making; and technology systems and information services that support managed care organizations. Additional information and previous press releases are available at the IMS HEALTH website: imshealth.com. nt.excite.com